S1: Blueprint Medicines stands beside patients with lung cancer
S2: It’s Lung Cancer Awareness Month
P1: How are you supporting Lung Cancer Awareness Month?
P Alt: Help us spread awareness during the month of November

[From: <Rep Name> (REPNAME@blueprintmedicines.com)]
[Sent: <MM/DD/YYYY HH:MM AM/PM>]
[To: <Last Name, First Name>]

[pick list]

[Dear]
[Hello]

[pick list]

[Dr. Last Name],
[First Name],
[First Name Last Name],

November is Lung Cancer Awareness Month. To help spread awareness, I would like to share some key statistics about lung cancer and some resources to provide your patients:

•

Lung cancer is one of the most common cancers in the United States¹

•

Non–small cell lung cancer (NSCLC) is the most prevalent type of lung cancer and accounts for about 84% of all lung cancer diagnoses²

•

It is estimated that over 198,000 people will be diagnosed with NSCLC in 2021^1,2

•

About 1 in 2 patients with metastatic NSCLC have biomarkers with approved, emerging, or evolving therapeutics^3,4

•	There are 9 known actionable biomarkers in NSCLC^3,4

•

Approximately 1%-2% of NSCLC cases are caused by abnormal RET genes⁵

Emerging Therapeutics=currently being studied in clinical trials; Evolving Therapeutics=either proof-of-concept studies or in a very early clinical stage; RET=rearranged during transfection.

Visit our website for potential resources for your patients with NSCLC, particularly your RET+ patients.

A list of advocacy groups and patient communities can be found by visiting our patient website.

Also available here are additional resources to share with your patients about biomarker testing in NSCLC.

I would love to set up a quick [pick list] [falsemeetingtruecalltruevideo chat] to learn more about your practice and how you are supporting Lung Cancer Awareness Month.

[pick list]
[Sincerely],
[Best],

[Rep photo]

[pick list]
[Rep name]
[Rep title]
Blueprint Medicines
[Rep phone number]
[Rep email address]

References: 1. National Cancer Institute. Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed September 22, 2021. 2. American Society of Clinical Oncology (ASCO). Lung cancer - non-small cell: statistics. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed September 15, 2021. 3. VanderLaan PA, Rangachari D, Costa DB. The rapidly evolving landscape of biomarker testing in non–small cell lung cancer. Cancer Cytopathol. 2021;129(3):179-181. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Non-Small Cell Lung Cancer V.6.2021.
© National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed October 7, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151-167.

Terms & Conditions | Privacy Policy | Contact | Unsubscribe

This e-mail is intended for U.S. healthcare professionals only.

This promotional e-mail is brought to you by Blueprint Medicines.

This e-mail is intended for the recipient identified above. If you have received this e-mail in error, please notify the sender immediately and delete the e-mail from your system.

To unsubscribe from this type of informational e-mail as delivered by your Blueprint Medicines representative, please click here. Regular communications between you and your Blueprint Medicines representative regarding standard business and meeting coordination activities may continue.

Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation.

The Genentech logo is a registered trademark of Genentech, Inc.

Blueprint Medicines Corporation
45 Sidney Street, Cambridge, MA 02139